Gilead Sciences (GILD) Reports 96-Wk Data from Phase 3 Study of Biktarvy (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for HIV-1 Treatment in Adults New to HIV Therapy
Tweet Send to a Friend
Gilead Sciences, Inc. (NASDAQ: GILD) today announced 96-week results from a Phase 3, randomized, double-blinded study (Study 1490) evaluating the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
